Cytoreductive Surgery and Intraperitoneal Chemohyperthermia for Recurrent Peritoneal Carcinomatosis from Ovarian Cancer

No abstract is available for this paper.

• Publication year

  2004

• Venue

  World Journal of Surgery

• Publication date

  2004-09-29

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/s00268-004-7461-xPMID 15573262
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Hyperthermia enhances the cytotoxicity and platinum-DNA adduct formation of lobaplatin and oxaliplatin in cultured SW 1573 cells

  2005cited by this paper
• Intraperitoneal antineoplastic drug delivery: rationale and results.

  2003cited by this paper
• Surgery combined with peritonectomy procedures and intraperitoneal chemohyperthermia in abdominal cancers with peritoneal carcinomatosis: a phase II study.

  2003cited by this paper
• Pharmacokinetic study of docetaxel in intraoperative hyperthermic i.p. chemotherapy for ovarian cancer

  2003cited by this paper
• Intraperitoneal chemotherapy for ovarian carcinoma: results of long-term follow-up.

  2002cited by this paper
• Population pharmacokinetics of cisplatin in patients with advanced ovarian cancer during intraperitoneal hyperthermia chemotherapy.

  2002cited by this paper
• Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: an intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Gr

  2001cited by this paper
• Chemohyperthermia for advanced abdominal malignancies: a new procedure with closed abdomen and previously performed anastomosis.

  2001cited by this paper
• Cytoreductive Surgery Followed by Intraperitoneal Hyperthermic Perfusion in the Treatment of Recurrent Epithelial Ovarian Cancer: A Phase II Clinical Study

  2001cited by this paper
• THE EFFECT OF DEBULKING SURGERY AFTER INDUCTION CHEMOTHERAPY ON THE PROGNOSIS IN ADVANCED EPITHELIAL OVARIAN CANCER

  2001cited by this paper
• Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan.

  2001cited by this paper
• Treatment of peritoneal carcinomatosis with intent to cure

  2000cited by this paper
• RESPONSE: re: randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results

  2000cited by this paper
• Extensive cytoreductive surgery combined with intra-operative intraperitoneal perfusion with cisplatin under hyperthermic conditions (OVHIPEC) in patients with recurrent ovarian cancer: a feasibility pilot.

  2000cited by this paper
• Research on the best chemohyperthermia technique of treatment of peritoneal carcinomatosis after complete resection.

  2000cited by this paper
• Cytoreductive Surgery and Intraperitoneal Chemotherapy for Peritoneal Surface Malignancies

  2000cited by this paper
• Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results.

  2000cited by this paper
• A pilot phase I trial of continuous hyperthermic peritoneal perfusion with high-dose carboplatin as primary treatment of patients with small-volume residual ovarian cancer

  1999cited by this paper
• Effets de la température intra-abdominale sur la diffusion tissulaire et tumorale du cisplatine intrapéritonéal dans un modèle de carcinose péritonéale chez le rat

  1999cited by this paper
• [The effect of intra-abdominal temperature on the tissue and tumor diffusion of intraperitoneal cisplatin in a model of peritoneal carcinomatosis in rats].

  1999cited by this paper
• Peritonectomy combined with intraperitoneal chemohyperthermia in abdominal cancer with peritoneal carcinomatosis: phase I-II study.

  1999cited by this paper
• Chemohyperthermic peritoneal perfusion for peritoneal dissemination in various intra-abdominal malignancies.

  1999cited by this paper
• Intraperitoneal cisplatin with regional hyperthermia in advanced ovarian cancer: pharmacokinetics and cisplatin-DNA adduct formation in patients and ovarian cancer cell lines.

  1998cited by this paper
• Phase II study of liposomal doxorubicin in refractory ovarian cancer: antitumor activity and toxicity modification by liposomal encapsulation.

  1997cited by this paper
• Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer.

  1997cited by this paper
• Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer.

  1996cited by this paper
• Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer

  1996cited by this paper
• Peritonectomy Procedures

  1995cited by this paper
• Lysosomal exocytosis induced by hyperthermia: a new model of cancer cell death. II. Effect on peritoneal macrophages.

  1995cited by this paper
• The effect of debulking surgery after induction chemotherapy on the prognosis in advanced epithelial ovarian cancer. Gynecological Cancer Cooperative Group of the European Organization for Research and Treatment of Cancer.

  1995cited by this paper
• Peritonectomy procedures.

  1995cited by this paper
• Pharmacokinetics and toxicity of intraperitoneal cisplatin combined with regional hyperthermia.

  1987cited by this paper
• Clinical delivery system for intraperitoneal hyperthermic chemotherapy.

  1980cited by this paper
• Chemotherapy of ovarian cancer.

  1978cited by this paper
• Selective lethal effect of supranormal temperatures on human neoplastic cells.

  1976cited by this paper

• Complications of HIPEC for ovarian cancer surgery: evaluation over two time periods

  2023cites this paper
• Prognostic role of the peritoneal cancer index in ovarian cancer patients who undergo cytoreductive surgery: a meta-analysis.

  2023cites this paper
• Prognosis Following Surgery for Recurrent Ovarian Cancer and Diagnostic Criteria Predictive of Cytoreduction Success: A Systematic Review and Meta-Analysis

  2023cites this paper
• Limitations of laparoscopy to assess the peritoneal cancer index and eligibility for cytoreductive surgery with HIPEC in peritoneal metastasis

  2022cites this paper
• Current Medical Care Situation of Patients in Germany Undergoing Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC)

  2022cites this paper
• The addition of sodium thiosulphate to hyperthermic intraperitoneal chemotherapy with cisplatin in ovarian cancer

  2021cites this paper
• Secondary Cytoreductive Surgery in Platinum-Sensitive Recurrent Ovarian Cancer: A Meta-Analysis

  2021cites this paper
• Survival Outcomes after Hyperthermic Intraperitoneal Chemotherapy for a First Ovarian Cancer Relapse: A Systematic Evidence-Based Review

  2021cites this paper
• Hyperthermic intraperitoneal chemotherapy in locally advanced and recurrent ovarian carcinoma: surgical and oncological outcomes in the Indian public healthcare system.

  2021cites this paper
• Intraperitoneal chemotherapy for ovarian cancer with peritoneal metastases, systematic review of the literature and focused personal experience.

  2021cites this paper
• Twelve-Year Single Center Experience Shows Safe Implementation of Developed Peritoneal Surface Malignancy Treatment Protocols for Gastrointestinal and Gynecological Primary Tumors

  2021cites this paper
• An overview and update of hyperthermic intraperitoneal chemotherapy in ovarian cancer

  2020cites this paper
• Current status of hyperthermic intraperitoneal chemotherapy (HIPEC) for ovarian cancer in the United States.

  2020cites this paper
• Can machine learning predict resecability of a peritoneal carcinomatosis?

  2019cites this paper
• Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy combined with liver resection for concurrent peritoneal and hepatic metastases of gastrointestinal and gynecological primary tumors.

  2019cites this paper
• Variation in Clinical Application of Hyperthermic Intraperitoneal Chemotherapy: A Review

  2019cites this paper
• Chirurgie de cyto-réduction et chimio-hyperthermie intrapéritonéale combinées à une résection hépatique pour métastases péritonéales et hépatiques synchrones d’origine digestive ou gynécologique

  2019cites this paper
• Cytoreductive Surgery and Hyperthermic Intraoperative Chemotherapy for Management of Peritoneal Carcinomatosis.

  2018cites this paper
• [Surgical treatment of peritoneal metastases from gynecological primary tumors].

  2018cites this paper
• Incorporation of paclitaxel-based hyperthermic intraperitoneal chemotherapy in patients with advanced-stage ovarian cancer treated with neoadjuvant chemotherapy followed by interval debulking surgery: a protocol-based pilot study

  2018cites this paper
• Hyperthermic intraperitoneal chemotherapy is an independent risk factor for development of acute kidney injury

  2018cites this paper
• Nephrotoxicity and long-term survival investigations for patients with peritoneal carcinomatosis using hyperthermic intraperitoneal chemotherapy with cisplatin: A retrospective cohort study.

  2018cites this paper
• Chirurgische Therapie bei peritonealen Metastasen gynäkologischer Primärtumoren

  2018cites this paper
• Surgical Management of Recurrent Epithelial Ovarian Cancer

  2018cites this paper
• Epithelial ovarian, fallopian tube, and primary peritoneal cancer

  2018cites this paper
• Progress in the management of primary and recurrent ovarian carcinomatosis with peritonectomy procedure and HIPEC in a high volume centre

  2017cites this paper
• 1st Evidence-based Italian Consensus Conference on Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Peritoneal Carcinosis from Ovarian Cancer

  2017cites this paper
• Importancia de la temperatura de la quimioterapia intraperitoneal intraoperatoria con paclitaxel en el tratamiento quirúrgico radical de la carcinomatosis peritoneal de origen ovárico. Hipertermia versus normotermia

  2017cites this paper
• Factors Affecting Perioperative Outcomes After CRS and HIPEC for Advanced and Recurrent Ovarian Cancer: A Prospective Single Institutional Study

  2017cites this paper
• Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for treatment of ovarian cancer

  2016cites this paper
• The role of Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Ovarian Cancer: A Review

  2016cites this paper
• Cytoreductive Surgery Plus Platinum-Based Hyperthermic Intraperitoneal Chemotherapy in Epithelial Ovarian Cancer: A Promising Integrated Approach to Improve Locoregional Control

  2016cites this paper
• Survival Impact of Secondary Cytoreductive Surgery for Recurrent Ovarian Cancer in an Asian Population.

  2015cites this paper
• The role of cytoreductive surgery and HIPEC in epithelial ovarian cancer.

  2015cites this paper
• Management of Special Issues

  2015cites this paper
• Should we use the hyperthermic intraperitoneal chemotherapy in the management of ovarian cancer? A literature review

  2015cites this paper
• Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy

  2015cites this paper
• Hyperthermic intraperitoneal chemotherapy for the treatment of ovarian cancer: A brief overview of recent results.

  2015cites this paper
• Hyperthermic intraperitoneal chemotherapy (HIPEC) and cytoreductive surgery (CRS) in ovarian cancer: A systematic review and meta-analysis.

  2015cites this paper
• Cytoreduction surgery with hyperthermic intraperitoneal chemotherapy in recurrent ovarian cancer improves progression‐free survival, especially in BRCA‐positive patients—A case‐control study

  2014cites this paper
• The role of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in the treatment of ovarian cancer relapse

  2014cites this paper
• Hyperthermic intraperitoneal chemotherapy (HIPEC) in ovarian cancer.

  2014cites this paper
• Peritoneal debulking/intraperitoneal chemotherapy—non‐sarcoma

  2014cites this paper
• Peritonectomy and hyperthermic chemotherapy in patients with advanced or recurrent ephitelial ovarian cancer: a single center cohort study.

  2014cites this paper
• Treatment of peritoneal carcinomatosis from ovarian cancer by surgical cytoreduction and hyperthermic intraperitoneal chemotherapy (HIPEC).

  2014cites this paper
• Security and efficiency of a closed-system, turbulent-flow circuit for hyperthermic intraperitoneal chemotherapy after cytoreductive ovarian surgery: perioperative outputs

  2014cites this paper
• Loco-regional cancer drug therapy: present approaches and rapidly reversible hydrophobization (RRH) of therapeutic agents as the future direction.

  2014cites this paper
• Survival Benefit of Hyperthermic Intraperitoneal Chemotherapy for Recurrent Ovarian Cancer: A Multi-institutional Case Control Study

  2014cites this paper
• Intraperitoneal chemotherapy against peritoneal carcinomatosis: current status and future perspective.

  2014cites this paper
• The incidence of cisplatin nephrotoxicity post hyperthermic intraperitoneal chemotherapy (HIPEC) and cytoreductive surgery

  2014cites this paper
• Intraperitoneal Chemotherapy from Armstrong to HIPEC: Challenges and Promise

  2014cites this paper
• Morbidity and mortality outcomes of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in patients with primary and recurrent advanced ovarian cancer.

  2014cites this paper
• The role of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in the treatment of ovarian cancer relapse

  2014cites this paper
• La chimiohyperthermie intrapéritonéale (CHIP) dans les cancers ovariens

  2014cites this paper
• The use of heated intraperitoneal chemotherapy for the treatment of gynecologic carcinomatosis

  2014cites this paper
• Natural history of epithelial ovarian cancer and its relation to surgical and medical treatment

  2013cites this paper
• Surgical cytoreduction for recurrent epithelial ovarian cancer.

  2013cites this paper
• Faisabilité, morbidité et survie de la chirurgie avec CHIP dans la prise en charge des récidives du cancer de l’ovaire

  2013cites this paper
• Peritoneal carcinomatosis.

  2013cites this paper
• Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in epithelial ovarian cancer: State of the art

  2013cites this paper
• Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for Recurrent Advanced Ovarian Carcinoma: Initial Experience in Mexico

  2013cites this paper
• Peritoneal carcinomatosis treated with cytoreductive surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for advanced ovarian carcinoma: a French multicentre retrospective cohort study of 566 patients.

  2013cites this paper
• [Feasibility, morbidity and survival of surgery combined with HIPEC in the management of recurrent ovarian cancer].

  2013cites this paper
• Cytoreduction and Hyperthermic Intraperitoneal Chemoperfusion in Women with Heavily Pretreated Recurrent Ovarian Cancer

  2012cites this paper
• Diagnosis and Management of Peritoneal Metastases from Ovarian Cancer

  2012cites this paper
• Current status and future directions of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in the treatment of ovarian cancer.

  2012cites this paper
• Cyto-reductive Surgery combined with Hyperthermic Intra-peritoneal Chemotherapy for Peritoneal Surface Malignancies: current treatment and results.

  2012cites this paper
• CHIP et cancer de l’ovaire : en finir avec les préjugés

  2012cites this paper
• Combined Cytoreductive Surgery and Perioperative Intraperitoneal Chemotherapy for the Treatment of Advanced Ovarian Cancer

  2012cites this paper
• Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for Persistent and Recurrent Advanced Ovarian Carcinoma: A Multicenter, Prospective Study of 246 Patients

  2012cites this paper
• Survival benefit of adding Hyperthermic IntraPEritoneal Chemotherapy (HIPEC) at the different time-points of treatment of ovarian cancer: review of evidence.

  2012cites this paper
• Estudio multivariante de los factores asociados con la morbilidad postoperatoria y la recurrencia tras citorreducción y quimioterapia intraperitoneal intraoperatoria hipertérmica (HIPEC) en pacientes con carcinomatosis peritoneal por carcinoma de ovario

  2012cites this paper
• Cytoreductive Surgery Combined with Hyperthermic Intraperitoneal Intraoperative Chemotherapy in the Treatment of Advanced Epithelial Ovarian Cancer

  2012cites this paper
• Hyperthermic intraperitoneal chemotherapy in ovarian cancer: rationale and clinical data

  2012cites this paper
• The role of FDG-PET/CT in ovarian cancer patients with high tumor markers or suspicious lesion on contrast-enhanced CT in evaluation of recurrence and/or in determination of intraabdominal metastases.

  2012cites this paper
• Therapeutic Strategies in Ovarian Cancer

  2012influential citation
• Intraperitoneal chemotherapy in ovarian cancer: a review of tolerance and efficacy

  2012cites this paper
• [HIPEC and ovarian carcinoma: base judgment on evidence].

  2012cites this paper
• Zytoreduktive Chirurgie in Kombination mit intraoperativer, intraperitonealer hyperthermer Chemoperfusion als Therapiekonzept bei peritoneal metastasierten Ovarialkarzinomen: Eine Literaturanalyse der vergangenen 10 Jahre

  2012cites this paper
• Heterogeneity in patients and methods. A problem for hyperthermic intraoperative intraperitoneal chemotherapy (HIPEC) in ovarian carcinoma.

  2011cites this paper
• Oxaliplatin‐based hyperthermic intraperitoneal chemotherapy in primary or recurrent epithelial ovarian cancer: A pilot study of 31 patients

  2011cites this paper
• The role of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in the management of recurrent advanced ovarian cancer: a prospective study.

  2011cites this paper
• Perioperative fast track program in intraoperative hyperthermic intraperitoneal chemotherapy (HIPEC) after cytoreductive surgery in advanced ovarian cancer.

  2011cites this paper
• Reappraisal of the role of hyperthermic intraperitoneal chemotherapy (HIPEC) in the management of ovarian cancer: a single institutional experience.

  2011cites this paper
• Place de la chimiothérapie hyperthermique intrapéritonéale (CHIP) dans la prise en charge du cancer de l’ovaire : expérience monocentrique institutionnelle

  2011cites this paper
• Cisplatin, a platinum-containing antineoplastic drug: perspectives on analytical chemistry and prevention of ototoxicity

  2010cites this paper
• Salvage cytoreduction for chemorefractory ovarian cancer with peritoneal carcinomatosis: A last chance or futile efforts?

  2010cites this paper
• The place of gynaecologic cancers in peritoneal surface oncology concept

  2010cites this paper
• Hyperthermic intraperitoneal chemotherapy ( HIPEC ) in optimally cytoreduced peritoneal carcinomatosis of gynecology origin : Does it provide survival advantage ?

  2010cites this paper
• Hyperthermic intraperitoneal chemotherapy added to the treatment of ovarian cancer. A review of achieved results and complications.

  2010cites this paper
• Peritoneal carcinosis of ovarian origin.

  2010cites this paper
• [Intraperitoneal chemotherapy in the treatment of advanced ovarian cancer].

  2010cites this paper
• Safety and potential benefit of hyperthermic intraperitoneal chemotherapy (HIPEC) in peritoneal carcinomatosis from primary or recurrent ovarian cancer

  2010cites this paper
• Hyperthermic intraperitoneal chemotherapy with oxaliplatin and without adjuvant chemotherapy in stage IIIC ovarian cancer.

  2010cites this paper
• Consolidation hyperthermic intraperitoneal chemotherapy using paclitaxel in patients with epithelial ovarian cancer

  2010cites this paper
• Cytoreductive surgery for recurrent ovarian cancer: a meta-analysis.

  2009cites this paper
• Hyperthermic Intraperitoneal Chemotherapy in Ovarian Cancer: First Report of the HYPER-O Registry

  2009cites this paper
• Intraoperative hyperthermic intraperitoneal chemotherapy after cytoreductive surgery in ovarian cancer peritoneal carcinomatosis: systematic review of current results

  2009influential citation
• Hyperthermic intraperitoneal chemotherapy in the management of ovarian cancer: A critical need for an evidence-based evaluation.

  2009cites this paper
• The role of hyperthermic intraperitoneal chemotherapy (HIPEC) in ovarian cancer.

  2009cites this paper